etomidate has been researched along with Liver Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, J; Li, N; Li, Q; Liu, C; Wang, X; Wu, Z; Xu, J; Yao, F; Zhang, L; Zhang, R; Zhou, H; Zhou, L; Zhou, S | 1 |
1 other study(ies) available for etomidate and Liver Neoplasms
| Article | Year |
|---|---|
Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.
Topics: Adenosine Triphosphate; Anesthetics, Intravenous; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemoembolization, Therapeutic; Etomidate; Humans; Janus Kinase 2; Liver Neoplasms; Signal Transduction; STAT3 Transcription Factor | 2023 |